Multiple myeloma (MM) clones reside in the bone marrow (BM), which plays a role in its survival and development. The interactions between MM and their neighboring mesenchymal stromal cells (MSCs) have been shown to promote MM growth and drug resistance. However, those interactions are often missing or misrepresented in traditional two-dimensional (2D) culture models. Application of novel three-dimensional (3D) models might recapitulate the BM niche more precisely, which will offer new insights into MM progression and survival. Here, we aimed to establish two 3D models, based on MSC spheroids and collagen droplets incorporating both MM cells and MSCs with the goal of replicating the native myeloma context of the BM niche. This approach revealed that although MSCs can spontaneously assemble spheroids with altered metabolic traits, MSC spheroid culture does not support the integration of MM cells. On the contrary, collagen-droplet culture supported the growth of both cell types. In collagen, MSC proliferation was reduced, with the correlating decrease in ATP production and Ki-67 expression, which might resemble in vivo conditions, rather than 2D abundance of nutrients and space. MSCs and MMs were distributed homogenously throughout the collagen droplet, with an apparent CXCL12 expression in MSCs. In addition, the response of MM cells to bortezomib was substantially reduced in collagen, indicating the importance of 3D culture in the investigation of myeloma cell behavior, as drug resistance is one of the most pertinent issues in cancer therapy.
Impact Statement
The application of three-dimensional models in the investigation of multiple myeloma will provide better insight into their behavior and drug resistance, allowing us to develop better treatment strategies. Here, we optimized a collagen-based approach that has shown to be reproducible, cost-effective, and already providing an altered feedback in therapy response.
Get full access to this article
View all access options for this article.
References
1.
AntoniD, BurckelH, JossetE, et al.Three-dimensional cell culture: A breakthrough in vivo. Int J Mol Sci, 2015; 16(3):5517–5527; doi: 10.3390/ijms16035517
2.
CostaEC, MoreiraAF, de Melo-DiogoD, et al.3D tumor spheroids: An overview on the tools and techniques used for their analysis. Biotechnol Adv, 2016; 34(8):1427–1441; doi: 10.1016/j.biotechadv.2016.11.002
3.
LanghansSA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol, 2018; 9:6; doi: 10.3389/fphar.2018.00006
4.
ImamuraY, MukoharaT, ShimonoY, et al.Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncol Rep, 2015; 33(4):1837–1843; doi: 10.3892/or.2015.3767
5.
LvD, HuZ, LuL, et al.Three-dimensional cell culture: A powerful tool in tumor research and drug discovery. Oncol Lett, 2017; 14(6):6999–7010; doi: 10.3892/ol.2017.7134
6.
ManierS, SaccoA, LeleuX, et al.Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol, 2012; 2012:157496; doi: 10.1155/2012/157496
7.
MeadsMB, GatenbyRA, DaltonWS. Environment-mediated drug resistance: A major contributor to minimal residual disease. Nat Rev Cancer, 2009; 9(9):665–674; doi: 10.1038/nrc2714
MaisoP, MogollónP, OcioEM, et al.Bone marrow mesenchymal stromal cells in multiple myeloma: Their role as active contributors to myeloma progression. Cancers, 2021; 13(11); doi: 10.3390/cancers13112542
10.
XuS, De VeirmanK, De BeckerA, et al.Mesenchymal stem cells in multiple myeloma: A therapeutical tool or target? Leukemia, 2018; 32(7):1500–1514; doi: 10.1038/s41375-018-0061-9
11.
GuoJ, ZhaoY, FeiC, et al.Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells. Cell Death Dis, 2018; 9(5):512; doi: 10.1038/s41419-018-0545-6
12.
LeeMW, RyuS, KimDS, et al.Mesenchymal stem cells in suppression or progression of hematologic malignancy: Current status and challenges. Leukemia, 2019; 33(3):597–611; doi: 10.1038/s41375-018-0373-9
13.
GaoY, ChiY, ChenY, et al.Multi-omics analysis of human mesenchymal stem cells shows cell aging that alters immunomodulatory activity through the downregulation of PD-L1. Nat Commun, 2023; 14(1):4373; doi: 10.1038/s41467-023-39958-5
14.
VincentT, MechtiN. Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Leuk Lymphoma, 2005; 46(6):803–811; doi: 10.1080/10428190500051448
15.
NeriP, BahlisNJ. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr Cancer Drug Targets, 2012; 12(7):776–796; doi: 10.2174/156800912802429337
16.
TeohHK, ChongPP, AbdullahM, et al.Small interfering RNA silencing of interleukin-6 in mesenchymal stromal cells inhibits multiple myeloma cell growth. Leuk Res, 2016; 40:44–53; doi: 10.1016/j.leukres.2015.10.004
JensenC, TengY. Is it time to start transitioning from 2D to 3D cell culture? Front Mol Biosci, 2020; 7:33; doi: 10.3389/fmolb.2020.00033
19.
JaukovićA, AbadjievaD, TrivanovićD, et al.Specificity of 3D MSC spheroids microenvironment: Impact on MSC behavior and properties. Stem Cell Rev Rep, 2020; 16(5):853–875; doi: 10.1007/s12015-020-10006-9
20.
AkasovR, Zaytseva-ZotovaD, BurovS, et al.Formation of multicellular tumor spheroids induced by cyclic RGD-peptides and use for anticancer drug testing in vitro. Int J Pharm, 2016; 506(1-2):148–157; doi: 10.1016/j.ijpharm.2016.04.005
21.
LourençoD, LopesR, PestanaC, et al.Patient-derived multiple myeloma 3D models for personalized medicine-are we there yet? Int J Mol Sci, 2022; 23(21); doi: 10.3390/ijms232112888
22.
PereiraAR, LipphausA, ErginM, et al.Modeling of the human bone environment: Mechanical stimuli guide mesenchymal stem cell-extracellular matrix interactions. Materials (Basel), 2021; 14(16); doi: 10.3390/ma14164431
23.
SarinVY, FergusonK, IanD, et al.Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis. Leukemia, 2020; 30(10):2754–2765.
24.
KouroukisTC, BaldassarreFG, HaynesAE, et al.Bortezomib in multiple myeloma: Systematic review and clinical considerations. Curr Oncol, 2014; 21(4):e573–e603; doi: 10.3747/co.21.1798
25.
ObengEA, CarlsonLM, GutmanDM, et al.Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 2006; 107(12):4907–4916; doi: 10.1182/blood-2005-08-3531
26.
PainulyU, KumarS. Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clin Med Insights Oncol, 2013; 7:53–73; doi: 10.4137/cmo.S7764
27.
FischerAH, JacobsonKA, RoseJ, et al.Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc, 2008; 2008:pdb.prot4986; doi: 10.1101/pdb.prot4986
28.
GiallongoC, DulcamareI, TibulloD, et al.CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment. Oncogenesis, 2022; 11(1):6; doi: 10.1038/s41389-022-00380-z
29.
TsaiAC, LiuY, YuanX, et al.Compaction, fusion, and functional activation of three-dimensional human mesenchymal stem cell aggregate. Tissue Eng Part A, 2015; 21(9–10):1705–1719; doi: 10.1089/ten.TEA.2014.0314
30.
HuangYH, MolaviO, AlshareefA, et al.Constitutive activation of STAT3 in myeloma cells cultured in a three-dimensional, reconstructed bone marrow model. Cancers (Basel), 2018; 10(6); doi: 10.3390/cancers10060206
31.
WaldschmidtJM, FruttigerSJ, WiderD, et al.Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma. J Cancer Res Clin Oncol, 2022; 148(5):1045–1055; doi: 10.1007/s00432-021-03854-6
32.
ZanettiC, KrauseDS. “Caught in the net”: The extracellular matrix of the bone marrow in normal hematopoiesis and leukemia. Exp Hematol, 2020; 89:13–25; doi: 10.1016/j.exphem.2020.07.010
33.
TancredTM, BelchAR, ReimanT, et al.Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. J Histochem Cytochem, 2009; 57(3):239–247; doi: 10.1369/jhc.2008.952200
34.
ReaganMR, GhobrialIM. Multiple myeloma mesenchymal stem cells: Characterization, origin, and tumor-promoting effects. Clin Cancer Res, 2012; 18(2):342–349; doi: 10.1158/1078-0432.Ccr-11-2212
35.
García-SánchezD, González-GonzálezA, Alfonso-FernándezA, et al.Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: Impact on disease progression. World J Stem Cells, 2023; 15(5):421–437; doi: 10.4252/wjsc.v15.i5.421
36.
RenZ, van AndelH, de LauW, et al.Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins. Blood, 2018; 131(9):982–994; doi: 10.1182/blood-2017-07-797050
37.
Marín-PayáJC, Díaz-BenitoB, MartinsLA, et al.Biomimetic 3D environment based on microgels as a model for the generation of drug resistance in multiple myeloma. Materials (Basel), 2021; 14(23); doi: 10.3390/ma14237121
38.
SunX, KaufmanPD. Ki-67: More than a proliferation marker. Chromosoma, 2018; 127(2):175–186; doi: 10.1007/s00412-018-0659-8
39.
de la PuenteP, MuzB, GilsonRC, et al.3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials, 2015; 73:70–84; doi: 10.1016/j.biomaterials.2015.09.017
40.
UllahTR. The role of CXCR4 in multiple myeloma: Cells’ journey from bone marrow to beyond. J Bone Oncol, 2019; 17:100253; doi: 10.1016/j.jbo.2019.100253
41.
JakubikovaJ, CholujovaD, HideshimaT, et al.A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: Biologic and clinical applications. Oncotarget, 2016; 7(47):77326–77341; doi: 10.18632/oncotarget.12643
42.
KhanAO, Rodriguez-RomeraA, ReyatJS, et al.Human bone marrow organoids for disease modeling, discovery, and validation of therapeutic targets in hematologic malignancies. Cancer Discov, 2023; 13(2):364–385; doi: 10.1158/2159-8290.Cd-22-0199
43.
NarayananNK, DuanB, ButcherJT, et al.Characterization of multiple myeloma clonal cell expansion and stromal Wnt/β-catenin signaling in hyaluronic acid-based 3D hydrogel. In Vivo, 2014; 28(1):67–73.
44.
BamR, KhanS, LingW, et al.Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. BMC Cancer, 2015; 15:864; doi: 10.1186/s12885-015-1892-7
45.
RybkowskaP, RadoszkiewiczK, KawalecM, et al.The metabolic changes between monolayer (2D) and three-dimensional (3D) culture conditions in human mesenchymal stem/stromal cells derived from adipose tissue. Cells, 2023; 12(1); doi: 10.3390/cells12010178
46.
KaminskaA, WedzinskaA, KotM, et al.Effect of long-term 3D spheroid culture on WJ-MSC. Cells, 2021; 10(4); doi: 10.3390/cells10040719
NiibeK, Ohori-MoritaY, ZhangM, et al.A shaking-culture method for generating bone marrow derived mesenchymal stromal/stem cell-spheroids with enhanced multipotency in vitro. Front Bioeng Biotechnol, 2020; 8:590332; doi: 10.3389/fbioe.2020.590332
49.
PereiraAR, TrivanovićD, StahlhutP, et al.Preservation of the naïve features of mesenchymal stromal cells in vitro: Comparison of cell- and bone-derived decellularized extracellular matrix. J Tissue Eng, 2022; 13:20417314221074453; doi: 10.1177/20417314221074453
50.
BaraJJ, RichardsRG, AliniM, et al.Concise review: Bone marrow-derived mesenchymal stem cells change phenotype following in vitro culture: Implications for basic research and the clinic. Stem Cells, 2014; 32(7):1713–1723; doi: 10.1002/stem.1649
51.
PereiraAR, TrivanovićD, HerrmannM. Approaches to mimic the complexity of the skeletal mesenchymal stem/stromal cell niche in vitro. Eur Cell Mater, 2019; 37:88–112; doi: 10.22203/eCM.v037a07
52.
SomaiahC, KumarA, MawrieD, et al.Collagen promotes higher adhesion, survival and proliferation of mesenchymal stem cells. PLoS One, 2015; 10(12):e0145068; doi: 10.1371/journal.pone.0145068
AlhallakK, JeskeA, de la PuenteP, et al.A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. Sci Rep, 2021; 11(1):19343; doi: 10.1038/s41598-021-98760-9
55.
SteinerN, RibattiD, WillenbacherW, et al.Marine compounds inhibit growth of multiple myeloma in vitro and in vivo. Oncotarget, 2015; 6(10):8200–8209; doi: 10.18632/oncotarget.3362
56.
KyleAH, HuxhamLA, ChiamAS, et al.Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture. Cancer Res, 2004; 64(17):6304–6309; doi: 10.1158/0008-5472.Can-04-1099
